AstraZeneca Covid Vaccine 79% Effective in U.S. Clinical Trial

Mar.22 — Johns Hopkins Center for Health Security Senior Scholar Jennifer Nuzzo discusses U.S. clinical trial data for AstraZeneca Plc’s coronavirus vaccine. She speaks on “Bloomberg Surveillance.” The Bloomberg School of Public Health is supported by Michael R. Bloomberg, founder and majority owner of Bloomberg LP, the parent company of Bloomberg News.

Articles You May Like

Introducing StockTracker Master Class Volume 1